These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7802310)

  • 21. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department.
    Berg ML; Idrees U; Ding R; Nesbit SA; Liang HK; McCarthy ML
    Drug Alcohol Depend; 2007 Jan; 86(2-3):239-44. PubMed ID: 16930865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Office-based treatment of opiate addiction.
    Heit HA; Gourlay DL
    N Engl J Med; 2003 Dec; 349(26):2567-8; author reply 2567-8. PubMed ID: 14695422
    [No Abstract]   [Full Text] [Related]  

  • 25. Buprenorphine: effective treatment of opioid addiction starts in the office.
    Fiellin DA
    Am Fam Physician; 2006 May; 73(9):1513-4. PubMed ID: 16719242
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation on drug dependence of buprenorphine.
    Liu ZM; Lü XX; Lian Z; Mu Y; Guo P; An X
    Acta Pharmacol Sin; 2003 May; 24(5):448-52. PubMed ID: 12740181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evidence of new opioid modulators for the treatment of addiction.
    Rodríguez-Arias M; Aguilar MA; Manzanedo C; Miñarro J
    Expert Opin Investig Drugs; 2010 Aug; 19(8):977-94. PubMed ID: 20629615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tramadol dependence: treatment with buprenorphine/naloxone.
    Ritvo JI; Koonce R; Thurstone CC; Causey HL
    Am J Addict; 2007; 16(1):67-8. PubMed ID: 17364425
    [No Abstract]   [Full Text] [Related]  

  • 29. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services
    Fed Regist; 2003 May; 68(99):27937-9. PubMed ID: 12762334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Narcotic analgesics. Part IV. Agonists-antagonists and total antagonists of opiate receptors. Perspectives for clinical use of narcotic analgesics].
    Dubitskiĭ AE; Beliaev AV; Ryzhiĭ SM; Volikovskaia EV; Butylin VIu; Davydov NIu
    Klin Khir (1962); 1993; (7-8):64-8. PubMed ID: 7511186
    [No Abstract]   [Full Text] [Related]  

  • 31. Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study.
    Tamaskar R; Parran TV; Heggi A; Brateanu A; Rabb M; Yu J
    J Addict Dis; 2003; 22(4):5-12. PubMed ID: 14723474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using agonist-antagonist opioids and antagonist drugs.
    Pasero C; McCaffery M
    Am J Nurs; 1999 Jan; 99(1 Pt 1):20, 23. PubMed ID: 9932048
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opiate addiction in China: current situation and treatments.
    Tang YL; Zhao D; Zhao C; Cubells JF
    Addiction; 2006 May; 101(5):657-65. PubMed ID: 16669899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opiate receptor pharmacology: mixed agonist/antagonist narcotics.
    Hameroff SR
    Contemp Anesth Pract; 1983; 7():27-43. PubMed ID: 6136392
    [No Abstract]   [Full Text] [Related]  

  • 37. Perioperative implications of buprenorphine maintenance treatment for opioid addiction.
    Gevirtz C; Frost EA; Bryson EO
    Int Anesthesiol Clin; 2011; 49(1):147-55. PubMed ID: 21239911
    [No Abstract]   [Full Text] [Related]  

  • 38. Detoxification and treating opioid dependence.
    de Jong CJ
    JAMA; 2006 Feb; 295(8):887; author reply 887-8. PubMed ID: 16493098
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Opioid detoxification under anesthesia: new scientific territory or established methods?].
    Peters J; Kienbaum P
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):259-60. PubMed ID: 10372214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.